m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation

Biological Psychiatry

Volumn 38, Issue 3, 1995, Pages 138-149

  Goodman, Wayne K ^a   McDougle, Christopher J ^b   Price, Lawrence H ^b   Barr, Linda C ^b   Hills, Oscar F ^b   Caplik, James F ^b,c   Charney, Dennis S ^b   Heninger, George R ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

meta chlorophenylpiperazine; Obsessive compulsive disorder; serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; PROLACTIN;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AFFECT; ANXIETY; AROUSAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; SEROTONIN; SEROTONIN AGONISTS;

EID: 0029119856     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(94)00235-U     Document Type: Article

References (32)

1. Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats
2. Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats
3. The serotonin hypothesis of obsessive compulsive disorder: Implications of pharmacologic challenge studies
4. mCPP, a central 5-HT agonist, is a metabolite of trazodone
5. Serotonin function in obsessive-compulsive disorder
6. m-CPP: a tool for studying behavioral responses associated with 5-HT1c receptors
7. Disposition and pharmacological effects of MCPP
8. The Yale-Brown Obsessive Compulsive Scale. I: development, use, and reliability
9. The Yale-Brown Obsessive Compulsive Scale, II: validity
10. Pharmacological challenges inobsessive compulsive disorder
11. Rating scales for obsessive compulsive disorder
12. Development of a rating scale for primary depressive illness
13. Neuroendocrine effects of serotonin agonists in rhesus monkeys, healthy humans and patients with depression or anxiety disorders: Effects of antidepressant treatment
14. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorders
15. Serotonergic function in obsessive-compulsive disorder
16. The MCCP challenge test in schizophrenia: Hormonal and behavioral responses
17. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects
18. m-chlorophenylpiperazine as a probe of serotonin function
19. Serotonin function in schizophrenia: Effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects
20. Serotonergic Challenges in Obsessive Compulsive Disorder
21. m-chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients: Evidence implicating serotonergic systems in the positive symptoms of schizophrenia
22. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers
23. Serotonin-releasing effects of substituted piperazines in vitro
24. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder
25. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and effect of metergoline prior to IV mCPP
26. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to metachlorophenylpiperazine in healthy human subjects
27. Serotonergic responsivity in obsessive-compulsive disorder
28. Serotonergic responsivity in obsessive-compulsive disorder